
Metagenomi Inc (MGX) Stock Forecast & Price Target
Metagenomi Inc (MGX) Analyst Ratings
Bulls say
Metagenomi Inc., a genetic medicines company, has developed a proprietary genome editing toolbox that shows significant promise in addressing various disorders, including Hemophilia A, with notable results showcased through durable FVIII levels of 80% after 19 months in clinical trials. The company's strategy includes a robust pipeline focused on in vivo gene editing while also exploring technology out licensing for ex vivo cell therapies, indicating diverse revenue-generating opportunities. With a strong commitment to developing curative therapeutics and a clear focus on innovative solutions within the genetic medicine field, Metagenomi is well-positioned for future growth and financial success.
Bears say
Metagenomi Inc. reported a net loss of $19.9 million in 2Q25, translating to a loss of $0.54 per share, reflecting ongoing financial challenges. The company faces significant risks, including potential delays in advancing its pipeline candidates through clinical assessments, which could hinder progress particularly in critical areas like Hemophilia A and TTR. Additionally, concerns regarding the possibility of long-term dilution risk further contribute to a negative outlook for the company's financial performance.
This aggregate rating is based on analysts' research of Metagenomi Inc and is not a guaranteed prediction by Public.com or investment advice.
Metagenomi Inc (MGX) Analyst Forecast & Price Prediction
Start investing in Metagenomi Inc (MGX)
Order type
Buy in
Order amount
Est. shares
0 shares